Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of Ottawa
$27,000.00
Exploring the translational potential and repair pathway of iMSCs to treat bronchopulmonary dysplasia
EF 2025-26
Résumé
Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants, driven by inflammation and impaired alveolar–vascular development. Our lab has shown that hyperoxia disrupts key lung cell populations through inflammatory and anti-angiogenic signaling pathways, highlighting cellular targets for mesenchymal stromal cell (MSC)–based repair. Current therapies provide respiratory support but do not restore injured lung tissue, underscoring the need for regenerative approaches. Umbilical cord–derived MSCs (UC-MSCs) have advanced to clinical translation, however, demonstrate donor to donor variability, whereas induced pluripotent stem cell-derived MSCs (iMSCs) offer a more consistent, scalable product. Early data from our lab suggests iMSC-mediated lung protection, yet their safety profile and mechanisms of repair are insufficiently characterized. This project will evaluate these gaps through clinical and preclinical evidence. Aim 1 will synthesize clinical evidence on iMSCs safety, feasibility and therapeutic efficacy in trials, with a systematic review and meta-analysis. We will additionally evaluate quality of harms and iMSC-product reporting. Aim 2 will compare iMSC- and UC-MSC-mediated lung transcriptional repair pathways in a BPD mouse model. Pups will be exposed to room air or hyperoxia (85% O2) and treated with PBS, iMSCs, or UC-MSCs. Left lungs will undergo histologic assessment to identify MSC-responsive tissues and single-nuclei RNA sequencing to identify transcriptional and signaling repair pathways. Right lungs will be used for confirmatory protein-level validation assays. Together, this work will describe the current landscape in iMSC clinical development and elucidate mechanisms of lung repair to advance effective iMSC-based therapies for BPD.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
580452
Name
Bhattacharyya Urmila
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the translational potential and repair pathway of iMSCs to treat bronchopulmonary dysplasia
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Bronchopulmonary Dysplasia; Clinical Trials; Hyperoxia; Lung Injury; Mesenchymal Stromal Cells; Pre-Term Infants; Regenerative Medicine; Safety; Single-Nuclei Rna Sequencing; Systematic Review
Abstract
Bronchopulmonary dysplasia (BPD) is a chronic lung disease in premature infants, driven by inflammation and impaired alveolar–vascular development. Our lab has shown that hyperoxia disrupts key lung cell populations through inflammatory and anti-angiogenic signaling pathways, highlighting cellular targets for mesenchymal stromal cell (MSC)–based repair. Current therapies provide respiratory support but do not restore injured lung tissue, underscoring the need for regenerative approaches. Umbilical cord–derived MSCs (UC-MSCs) have advanced to clinical translation, however, demonstrate donor to donor variability, whereas induced pluripotent stem cell-derived MSCs (iMSCs) offer a more consistent, scalable product. Early data from our lab suggests iMSC-mediated lung protection, yet their safety profile and mechanisms of repair are insufficiently characterized. This project will evaluate these gaps through clinical and preclinical evidence. Aim 1 will synthesize clinical evidence on iMSCs safety, feasibility and therapeutic efficacy in trials, with a systematic review and meta-analysis. We will additionally evaluate quality of harms and iMSC-product reporting. Aim 2 will compare iMSC- and UC-MSC-mediated lung transcriptional repair pathways in a BPD mouse model. Pups will be exposed to room air or hyperoxia (85% O2) and treated with PBS, iMSCs, or UC-MSCs. Left lungs will undergo histologic assessment to identify MSC-responsive tissues and single-nuclei RNA sequencing to identify transcriptional and signaling repair pathways. Right lungs will be used for confirmatory protein-level validation assays. Together, this work will describe the current landscape in iMSC clinical development and elucidate mechanisms of lung repair to advance effective iMSC-based therapies for BPD.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Bhattacharyya, Urmila
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~